These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 22752871)

  • 1. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
    Crook DW; Walker AS; Kean Y; Weiss K; Cornely OA; Miller MA; Esposito R; Louie TJ; Stoesser NE; Young BC; Angus BJ; Gorbach SL; Peto TE;
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S93-103. PubMed ID: 22752871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
    Figueroa I; Johnson S; Sambol SP; Goldstein EJ; Citron DM; Gerding DN
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S104-9. PubMed ID: 22752857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
    Nelson RL; Suda KJ; Evans CT
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
    Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
    Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
    Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL
    Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.
    Weiss K; Allgren RL; Sellers S
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S110-5. PubMed ID: 22752858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
    Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
    J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
    Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
    Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
    Watt M; Dinh A; Le Monnier A; Tilleul P
    J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
    Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
    Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
    Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile.
    Eyre DW; Babakhani F; Griffiths D; Seddon J; Del Ojo Elias C; Gorbach SL; Peto TE; Crook DW; Walker AS
    J Infect Dis; 2014 May; 209(9):1446-51. PubMed ID: 24218500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
    Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
    Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
    Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
    Tannock GW; Munro K; Taylor C; Lawley B; Young W; Byrne B; Emery J; Louie T
    Microbiology (Reading); 2010 Nov; 156(Pt 11):3354-3359. PubMed ID: 20724385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.